Status:

UNKNOWN

Droplet-BC Screening Test for the Detection of Breast Cancer, the DROPLET-BC Study

Lead Sponsor:

Preferred Medicine, Inc

Collaborating Sponsors:

M.D. Anderson Cancer Center

Conditions:

Breast Carcinoma

Eligibility:

All Genders

18+ years

Brief Summary

This study investigates if a new type of test called Droplet-BC screening test can classify breast cancer patients from non-cancer volunteers by circulating small-noncoding RNA in the blood with a sta...

Detailed Description

PRIMARY OBJECTIVE: I. To determine the sensitivity and specificity of the Droplet-BC screening test for distinguishing breast cancer (BC) patients from non-cancer volunteers, using reference data con...

Eligibility Criteria

Inclusion

  • BREAST CANCER PATIENTS: Newly diagnosed with breast cancer
  • BREAST CANCER PATIENTS: Not received cancer treatment for newly diagnosed with breast cancer
  • BREAST CANCER PATIENTS: Able to comprehend, sign, and date the written informed consent document to participate in the study
  • BREAST CANCER PATIENTS: Able and willing to provide a one-time blood sample
  • BREAST CANCER PATIENTS: Age \>= 18 years old
  • NON-CANCER VOLUNTEERS: Have undergone a screening mammogram
  • NON-CANCER VOLUNTEERS: Not currently taking any drugs for cancer treatment or any cancer prevention medication
  • NON-CANCER VOLUNTEERS: Able to comprehend, sign, and date the written informed consent document to participate in this study
  • NON-CANCER VOLUNTEERS: Able and willing to provide blood samples according to provided written instructions
  • NON-CANCER VOLUNTEERS: Seen by a provider (physician or advanced practice nurse \[APN\]) in the Cancer Prevention clinic at MD Anderson Cancer Center or other participating sites
  • NON-CANCER VOLUNTEERS: Age \>= 18 years old

Exclusion

  • BREAST CANCER PATIENTS: Known current pregnancy
  • BREAST CANCER PATIENTS: History of breast cancer treatment in the past
  • BREAST CANCER PATIENTS: Participation in any interventional clinical study within the previous 30 days in which an experimental treatment is administered or might be administered through a randomized assignment of the subject to one or more study groups
  • BREAST CANCER PATIENTS: Any condition that, in the opinion of the investigator, should preclude participation in the study
  • NON-CANCER VOLUNTEERS: Known current pregnancy
  • NON-CANCER VOLUNTEERS: History of breast cancer (breast ductal carcinoma in situ \[DCIS\] and invasive)
  • NON-CANCER VOLUNTEERS: History of any cancer except non-melanoma skin cancer and cervical dysplasia
  • NON-CANCER VOLUNTEERS: Participation in any interventional clinical study within the previous 30 days in which experimental treatment is administered or might be administered through a randomized assignment of the subject to one or more study groups
  • NON-CANCER VOLUNTEERS: Any condition that in the opinion of the investigator, should preclude participation in the study

Key Trial Info

Start Date :

November 3 2020

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 31 2022

Estimated Enrollment :

1200 Patients enrolled

Trial Details

Trial ID

NCT04671498

Start Date

November 3 2020

End Date

December 31 2022

Last Update

June 21 2022

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Northwestern University Feinberg School of Medicine

Chicago, Illinois, United States, 60611

2

Roswell Park Comprehensive Cancer Center

Buffalo, New York, United States, 14263

3

M D Anderson Cancer Center

Houston, Texas, United States, 77030

Droplet-BC Screening Test for the Detection of Breast Cancer, the DROPLET-BC Study | DecenTrialz